2207-75-2 Oxonic acid potassium salt AKSci J98526
 
 
Loading Please Wait...
  J98526    AKSci Bulk Reagent
Oxonic acid potassium salt
, 95%
 
4,6-Dihydroxy-1,3,5-triazine-2-carboxylic acid potassium salt
Allantoxanic acid
Potassium oxonate




IDENTITY
CAS Number:2207-75-2
MDL Number:MFCD00010565
MF:C4H2KN3O4
MW:195.17
EINECS:218-627-5
BRN:4049961
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:>300°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

REVIEW

 Oxonic acid potassium salt is a biochemical modulator in the tegafur/gimeracil/oxonic acid potassium salt combination anticancer drug, which is used for the treatment of advanced gastric cancer and hepatocellular carcinoma. Due to its low permeability, oxonic acid potassium salt stays in the gut, where it reduces the production of 5-fluorouracil by blocking the enzyme orotate phosphoribosyltransferase. Lower 5-fluorouracil levels in the gut result in a lower gastrointestinal toxicity. A similar approach is present in S-1-gimeracil and oteracil potassium used for the treatment of gastric cancer.

REFERENCES
[1]Piskala, A.; Gut, J. Nucleic acid components and their analogs. XX. Synthesis of oxonic acid (2,4-dioxo-1,2,3,4-tetrahydro-1,3,5-triazine-6-carboxylic acid) and the acetylation of 2,4-dioxohexahydro-1,3,5-triazines Collection of Czechoslovak Chemical Communications (1962), 27, 1562-71.
[2] Piskala, Alois; Gut, Jiri Potassium 1,2,3,4-tetrahydro-2,4-dioxo-s-triazine-6-carboxylate (potassium 5-aza-orotate). Cyclocondensation of biuret with ethyl potassium oxalate Edited by Townsend, Leroy B.; Tipson, R. Stuart , Nucleic Acid Chem. (1978), 1, 93-5.
[3] Sugi, Mitsuyo; Igi, Masami Preparation of potassium oxonate by oxidation of allantoin using alkali metal hypohalite. Eur. Pat. Appl. (1999), EP 957096 A1 19991117.
[4] Kobayakawa M, Kojima Y.Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193-201.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 19, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Chemotherapeutics


PubChem